Raoul S. Concepcion, MD, FACS, Urology Associates P.C., Nashville, Tennessee, discusses what combinations of immunotherapy for prostate cancer treatment are most promising. Interview produced by Prostatepedia Keywords: combination immuonotherapy, enzalutamide, abiraterone, Provenge, Radium 223, prostate cancer Summary: In 2017, immunotherapy has been a popular approach for treating all tumor types. However, in this video, Dr. Concepcion explains specific recent advances in using immunotherapy for prostate cancer. He also discusses one of the toughest questions facing urologists today – can we combine immunotherapeutic agents with other treatments? Since the only FDA approved immunotherapy, Sipuleucel-T, or PROVENGE, won’t attack androgen receptors, can we combine...Read More
Raoul S. Concepcion, MD
The Comprehensive Prostate Center
Raoul S. Concepcion, MD, FACS, is the current Medical Director of The Comprehensive Prostate Center in Nashville TN and also a Clinical Assistant Professor in the Department of Urology, Vanderbilt School of Medicine. He is a Past President of the Large Urology Group Practice Association (LUGPA), a not for profit entity representing the interests of over 2,500 urologists in the U.S. affiliated with large single specialty groups.
Dr. Concepcion was a General Surgery and Urology Resident at Vanderbilt University School of Medicine from 1984-1989. He served as Chief Urology Resident from 1989-1990 and was also a research fellow in the Light Laboratories at Vanderbilt. He has been in practice since 1990, with his major clinical interest being Urologic Oncology, specializing in advanced prostate and bladder cancer and lower urinary tract reconstruction. He is Board Certified by the American Urological Association (AUA) and is a member of that organization, as well as the Southeastern Section of the AUA, Society of Urologic Oncology, American College of Surgeon and the Nashville Surgical Society.
From a research perspective, Dr. Concepcion has been actively in involved in basic science and clinical research since his days at Vanderbilt. Dr. Concepcion has been either the principal investigator (PI) or Co-PI on many clinical trials since the 1990’s (see enclosed CV). The focus as of recent has been in the Castration Resistant Prostate Cancer (CRPC) patients, as well as biomarker development. Along with two other urologists, he recently started CUSP, a Urology Specific Clinical Trials Organization that specializes in site and patient accrual for the pharmaceutical and bio lab industries.
Articles by Raoul S. Concepcion, MD
Ask the Expert: What Tools Can Be Used to Predict Who Will Respond to Certain Prostate Cancer Drugs?
Posted by Raoul S. Concepcion, MD | Oct 2017
Raoul S. Concepcion, MD, FACS, Urology Associates P.C., Nashville, Tennessee, discusses if there are molecular markers to guide appropriate therapy in treating metastatic castration resistant prostate cancer patients. Interview produced by Prostatepedia Keywords: AR-V7, Radium-223, androgen receptor, enzalutamide, abiraterone, metastatic castration resistant prostate...Read More
Posted by Raoul S. Concepcion, MD | Sep 2017
Raoul S. Concepcion, MD, FACS, The Comprehensive Prostate Center, Nashville, Tennessee, gives an overview of the targeting of the androgen receptor in the management of prostate cancer. To view slides from Dr. Concepcion’s presentation at the 18th Annual Future Directions in Urology Symposium, click here. Keywords: prostate cancer, androgen receptor...Read More
Posted by Raoul S. Concepcion, MD | Apr 2017
Dr. Raoul S. Concepcion presented “Targeting AR in Castration-Resistant Prostate Cancer” at the 27th annual International Prostate Cancer Update meeting on Thursday, January 26, 2017. Keywords: prostate cancer, abiraterone, androgen, ARV7, dihydrotestosterone, enzalutamide, ligand, PSA, testosterone How to cite: Concepcion, Raoul S. “Targeting AR in Castration-Resistant Prostate Cancer” January 26, 2017. Accessed Dec 2017. https://grandroundsinurology.com/targeting-ar-castration-resistant-prostate-cancer Transcript Targeting AR in Castration-Resistant Prostate Cancer My goal today, we’re going to talk about targeting androgen receptor in castration-resistant prostate cancer. And these are my disclosures Where I want to go with this talk is I’m not going to talk too much about drugs. Neal...Read More
Posted by Raoul S. Concepcion, MD | Apr 2017
Dr. Raoul S. Concepcion presented “What’s New in Immunotherapy for Prostate Cancer?” at the 27th annual International Prostate Cancer Update meeting on Thursday, January 26, 2017. Keywords: prostate cancer, antigen, CTLA-4, immunotherapy, metastatic, prostatectomy, PSA, Sipuleucel-T, T-cell, immunotherapy for prostate cancer How to cite: Concepcion, Raoul S. “What’s New in Immunotherapy?” January 26, 2017. Accessed Dec 2017. https://grandroundsinurology.com/whats-new-immunotherapy Summary for Immunotherapy for Prostate Cancer: Dr. Raoul S. Concepcion discusses the shift in urology practices toward using immunotherapy for prostate cancer and bladder cancer, and the rise of checkpoint inhibitors. He cites trials of sipuleucel-T and PROSTVAC-Tricom. Edited Transcript ...Read More